WO2010018458A3 - Phenol derivatives as hif-alpha modulators - Google Patents

Phenol derivatives as hif-alpha modulators Download PDF

Info

Publication number
WO2010018458A3
WO2010018458A3 PCT/IB2009/006751 IB2009006751W WO2010018458A3 WO 2010018458 A3 WO2010018458 A3 WO 2010018458A3 IB 2009006751 W IB2009006751 W IB 2009006751W WO 2010018458 A3 WO2010018458 A3 WO 2010018458A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
hif
phenol derivatives
treating
alpha modulators
Prior art date
Application number
PCT/IB2009/006751
Other languages
French (fr)
Other versions
WO2010018458A2 (en
Inventor
Yong Rae Hong
Dongkyu Shin
Seonggu Ro
Joong Myung Cho
Hyun Tae Kim
Jun Hee Lee
Jeong Mi Kim
Whee Seong Lee
Jong-Ryoo Choi
Original Assignee
Crystalgenomics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics, Inc. filed Critical Crystalgenomics, Inc.
Publication of WO2010018458A2 publication Critical patent/WO2010018458A2/en
Publication of WO2010018458A3 publication Critical patent/WO2010018458A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed herein are hydroxyaryl or hydroxyheteroaryl derivative compounds, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIFα in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF -related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.
PCT/IB2009/006751 2008-08-12 2009-08-12 Phenol derivatives and methods of use thereof WO2010018458A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8832408P 2008-08-12 2008-08-12
US61/088,324 2008-08-12

Publications (2)

Publication Number Publication Date
WO2010018458A2 WO2010018458A2 (en) 2010-02-18
WO2010018458A3 true WO2010018458A3 (en) 2010-04-08

Family

ID=41578266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006751 WO2010018458A2 (en) 2008-08-12 2009-08-12 Phenol derivatives and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2010018458A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
MY162507A (en) 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011130908A1 (en) * 2010-04-21 2011-10-27 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2977050A1 (en) 2010-10-08 2016-01-27 Nivalis Therapeutics, Inc. Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
WO2012083165A1 (en) 2010-12-16 2012-06-21 N30 Pharmaceuticals, Llc Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
RS55737B1 (en) 2011-09-02 2017-07-31 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
TWI606048B (en) 2013-01-31 2017-11-21 帝人製藥股份有限公司 Azolebenzene derivatives
JP2017114765A (en) * 2014-04-25 2017-06-29 大正製薬株式会社 Heteroaryl compound substituted with triazolyl
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
DK3176165T3 (en) 2014-07-30 2019-01-02 Teijin Pharma Ltd CRYSTAL OF AZOLBENZENE DERIVATIVE AS XANTHINOXIDASE INHIBITOR
KR102474325B1 (en) 2014-07-30 2022-12-05 데이진 화-마 가부시키가이샤 Azole benzene derivative and crystal thereof
US20170217948A1 (en) 2014-07-30 2017-08-03 Teijin Pharma Limited Xanthine oxidase inhibitor
CN107250130B (en) * 2015-02-04 2019-11-08 Beyondbio株式会社 Heterocyclic compound and pharmaceutical composition comprising it
CR20210055A (en) 2015-02-27 2021-04-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
TW202016075A (en) 2018-05-24 2020-05-01 大陸商蘇州盛迪亞生物醫藥有限公司 Method of preparing alkynyl pyridine prolyl hydroxylase inhibitor
CN112566906A (en) * 2018-07-26 2021-03-26 多曼治疗学公司 Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4
WO2021045584A1 (en) * 2019-09-06 2021-03-11 비욘드바이오주식회사 2'-amino-6-(2-amino-6-methylpyrimidine-4-yl)-3'-fluoro-[2,4'-bipyridine]-5-ol dihydrochloride and pharmaceutical composition comprising same
KR102501514B1 (en) * 2019-09-06 2023-02-21 비욘드바이오주식회사 2'-Amino-6-(2-amino-6-(1-isopropylpiperidin-4-yl)-5-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol trihydrochloride and pharmaceutical composition comprising the same
KR20210029693A (en) * 2019-09-06 2021-03-16 비욘드바이오주식회사 2,6-Bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and pharmaceutical composition comprising the same

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093841A2 (en) * 2000-06-05 2001-12-13 Novuspharma S.P.A. Barbituric acid analogs as therapeutic agents
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005118580A2 (en) * 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
US20070092500A1 (en) * 2004-08-13 2007-04-26 Healthpartners Research Foundation Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
WO2008130508A1 (en) * 2007-04-18 2008-10-30 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137084A2 (en) * 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2009073497A2 (en) * 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) * 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093841A2 (en) * 2000-06-05 2001-12-13 Novuspharma S.P.A. Barbituric acid analogs as therapeutic agents
WO2005118580A2 (en) * 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US20070092500A1 (en) * 2004-08-13 2007-04-26 Healthpartners Research Foundation Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
WO2008130508A1 (en) * 2007-04-18 2008-10-30 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137084A2 (en) * 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2009073497A2 (en) * 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) * 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HODGES, YVONNE K. ET AL: "Paradoxical Effects of Iron Chelation on Growth of Vascular Endothelial Cells", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY , 45(6), 539-544 CODEN: JCPCDT; ISSN: 0160-2446, 2005, XP002567215 *
LARUSCH, GRETCHEN A. ET AL: "Nutlin3 Blocks Vascular Endothelial Growth Factor Induction by Preventing the Interaction between Hypoxia Inducible Factor 1.alpha. and Hdm2", CANCER RESEARCH , 67(2), 450-454 CODEN: CNREA8; ISSN: 0008-5472, 2007, XP002567214 *

Also Published As

Publication number Publication date
WO2010018458A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010018458A3 (en) Phenol derivatives as hif-alpha modulators
WO2009037570A3 (en) Pyridine derivatives and methods of use thereof
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010021693A3 (en) Mif modulators
MX2009012595A (en) Spiroindolinone derivatives.
WO2011140202A3 (en) Mif modulators
WO2008067257A8 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2011126903A3 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
PH12014502721A1 (en) IMIDAZO[1,2-b] PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
EP4289838A3 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2008127349A3 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
WO2009089494A3 (en) Pharmaceutical compositions
WO2009143039A3 (en) Heterocyclic compounds as factor ixa inhibitors
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
IL191475A (en) Use of 40-o-(2-hydroxyethyl)-rapamycin for the manufacture of a medicament for the treatment of pancreatic neuroendocrine tumors
WO2013082345A8 (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
WO2008153793A3 (en) Gamma secretase modulators
WO2008011173A3 (en) Improvement of arginase levels/activity
WO2010138598A3 (en) Lxr modulators
WO2009120810A3 (en) Neurodegenerative disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774922

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09774922

Country of ref document: EP

Kind code of ref document: A2